Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 14/20 | 0.38 |
| ▸ | VEGFA | P15692 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23782968 | 0.80 | PGR (0.38) | EPAS1VEGFAPGRCYP11B1CYP11B2 | |
| SCHEMBL326748 | 0.77 | CYP11B1 (0.38) | EPAS1VEGFACYP11B1CYP11B2 | |
| SCHEMBL16798084 | 0.74 | CYP11B1 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL16800617 | 0.74 | CYP11B1 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL29741125 | 0.74 | CYP11B1 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL17514572 | 0.72 | PANK3 (0.35) | CYP11B1CYP11B2HTR7FPR1FPR2 | |
| SCHEMBL27203873 | 0.71 | CYP11B1 (0.35) | EPAS1VEGFACYP11B1CYP11B2 | |
| SCHEMBL29854658 | 0.71 | CYP11B1 (0.35) | EPAS1VEGFACYP11B1CYP11B2 | |
| SCHEMBL26183123 | 0.70 | EPAS1 (0.41) | EPAS1VEGFAPGRCYP11B1CYP11B2 | |
| SCHEMBL17514714 | 0.69 | DRD2 (0.37) | PGRCYP11B1CYP11B2HTR7FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178780-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | EPAS1 4245/4885VEGFA 4880/4885PGR 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.